A Study of CBX-12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Phase 2
40
about 1.1 years
18+
Female only
17 sites in AZ, CA, CT +10
About this study
This trial is testing a treatment called CBX-12 in women with ovarian cancer that has not responded to platinum chemotherapy. The goal is to see if this treatment is safe and effective.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take CBX-12
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Percentage of Subjects With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]
Secondary: Incidence of Subjects With Treatment Emergent Adverse Events (TEAEs), Median Duration of Response (DoR), Plasma levels of CBX-12 (Cmax), Plasma levels of CBX-12 (Tmax), Plasma levels of Exatecan (Cmax), Plasma levels of Exatecan (Tmax), Progression-Free Survival (PFS)
Oncology